FindMyRecallSubscribe
Class III: unlikely to cause harmOngoing

Padagis US Evamist Recall

Evamist (estradiol transdermal spray), 1

Padagis US LLC · Minneapolis, MN

Risk level
Class III
Reported by FDA
Mar 22, 2023
Recall ID
D-0464-2023
Check your lot numberHow we source this data

Summary

Padagis US recalled Evamist starting Feb 21, 2023. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0464-2023 on Mar 22, 2023. Reason: Failed Content Uniformity Specifications: The Spray Content Uniformity (SCU) requirement for Standard Deviation did not meet the requirement at the 18-month stability time point. Status: Ongoing.

Why it was recalled

Failed Content Uniformity Specifications: The Spray Content Uniformity (SCU) requirement for Standard Deviation did not meet the requirement at the 18-month stability time point.

Product description

Evamist (estradiol transdermal spray), 1.53 mg of estradiol per spray, 0.27 fl oz (8.1 mL) per metered-dose pump, Rx Only, Manufactured by DPT Laboratories, Ltd San Antonio, TX 78215, Manufactured for: Perrigo, Allegan, Minnapolis, MN 55427, NDC: 0574-2067-27

Lot numbers, UPCs & expiration codes

Lot# SCDR, Exp 02/2024

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0464-2023
Classification
Class III
Status
Ongoing
Recall initiated
Feb 21, 2023
FDA report date
Mar 22, 2023
Quantity
43,238 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Padagis US LLC

Original FDA data

Every field from FDA enforcement report D-0464-2023, exactly as published.

Show all FDA fields
City
Minneapolis
State
MN
Status
Ongoing
Country
United States
Event ID
91771
Address
3940 Quebec Ave N
Code information
Lot# SCDR, Exp 02/2024
Postal code
55427-1244
Report date
Mar 22, 2023
Product type
Drugs
Recall number
D-0464-2023
Classification
Class III
Recalling firm
Padagis US LLC
Product quantity
43,238 cartons
Reason for recall
Failed Content Uniformity Specifications: The Spray Content Uniformity (SCU) requirement for Standard Deviation did not meet the requirement at the 18-month stability time point.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Evamist (estradiol transdermal spray), 1.53 mg of estradiol per spray, 0.27 fl oz (8.1 mL) per metered-dose pump, Rx Only, Manufactured by DPT Laboratories, Ltd San Antonio, TX 78215, Manufactured for: Perrigo, Allegan, Minnapolis, MN 55427, NDC: 0574-2067-27
Distribution pattern
Nationwide in the USA
Recall initiation date
Feb 21, 2023
Initial firm notification
Letter
Center classification date
Mar 10, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0464-2023, published Mar 22, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls